Jpmorgan Chase & CO Ocugen, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding OCGN
# of Institutions
124Shares Held
78.3MCall Options Held
535KPut Options Held
523K-
Black Rock Inc. New York, NY17.9MShares$13.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.9MShares$13.1 Million0.0% of portfolio
-
State Street Corp Boston, MA15.8MShares$12.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.28MShares$4.83 Million0.0% of portfolio
-
Gmt Capital Corp Atlanta, GA2.45MShares$1.89 Million0.1% of portfolio
About Ocugen, Inc.
- Ticker OCGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,566,000
- Market Cap $167M
- Description
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...